Shishir K Maithel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4115456/publications.pdf

Version: 2024-02-01

344 papers	9,613 citations	47006 47 h-index	76900 74 g-index
345 all docs	345 docs citations	345 times ranked	9771 citing authors

#	Article	IF	Citations
1	Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology. Ca-A Cancer Journal for Clinicians, 2017, 67, 362-377.	329.8	364
2	Gallbladder Cancer: expert consensus statement. Hpb, 2015, 17, 681-690.	0.3	334
3	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 1015-1027.	1.6	301
4	Choledochal Cysts: Presentation, Clinical Differentiation, and Management. Journal of the American College of Surgeons, 2014, 219, 1167-1180.	0.5	193
5	A Multi-institutional International Analysis of Textbook Outcomes Among Patients Undergoing Curative-Intent Resection of Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2019, 154, e190571.	4.3	149
6	Rates and Patterns of Recurrence after Curative Intent Resection for Gastric Cancer: A United States Multi-Institutional Analysis. Journal of the American College of Surgeons, 2014, 219, 664-675.	0.5	139
7	Transplantation Versus Resection for Hilar Cholangiocarcinoma. Annals of Surgery, 2018, 267, 797-805.	4.2	137
8	Can hepatic resection provide a longâ€term cure for patients with intrahepatic cholangiocarcinoma?. Cancer, 2015, 121, 3998-4006.	4.1	131
9	Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2020, 155, 823.	4.3	116
10	Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. Annals of Surgery, 2019, 270, 400-413.	4.2	113
11	Importance of Low Preoperative Platelet Count in Selecting Patients for Resection of Hepatocellular Carcinoma: A Multi-Institutional Analysis. Journal of the American College of Surgeons, 2011, 212, 638-648.	0.5	105
12	Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis. Annals of Surgery, 2021, 274, e1187-e1195.	4.2	105
13	Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. JAMA Surgery, 2016, 151, 365.	4.3	102
14	Presentation and Clinical Outcomes of Choledochal Cysts in Children and Adults. JAMA Surgery, 2015, 150, 577.	4.3	98
15	Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System. Journal of Gastrointestinal Surgery, 2018, 22, 52-59.	1.7	92
16	Report of a Simplified Frailty Score Predictive ofÂShort-Term Postoperative Morbidity and Mortality. Journal of the American College of Surgeons, 2015, 220, 904-911.e1.	0.5	87
17	Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2017, 115, 696-703.	1.7	85
18	Prognostic Performance of Different Lymph Node Staging Systems After Curative Intent Resection for Gastric Adenocarcinoma. Annals of Surgery, 2015, 262, 991-998.	4.2	83

#	Article	IF	Citations
19	Association of Preoperative Risk Factors With Malignancy in Pancreatic Mucinous Cystic Neoplasms. JAMA Surgery, 2017, 152, 19.	4.3	82
20	Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. Annals of Surgical Oncology, 2016, 23, 134-141.	1.5	76
21	Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. Hpb, 2017, 19, 901-909.	0.3	74
22	Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival. JAMA Surgery, 2017, 152, 143.	4.3	74
23	Recurrence Patterns and Timing Courses Following Curative-Intent Resection for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 2549-2557.	1.5	74
24	Number of Lymph Nodes Removed and Survival after Gastric Cancer Resection: An Analysis from the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2015, 221, 291-299.	0.5	73
25	Ice Packs Reduce Postoperative Midline Incision Pain and Narcotic Use: A Randomized Controlled Trial. Journal of the American College of Surgeons, 2014, 219, 511-517.	0.5	72
26	Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. Journal of the American College of Surgeons, 2016, 222, 480-490.	0.5	71
27	Effect of Perioperative Transfusion on Recurrence and Survival after Gastric Cancer Resection: A 7-Institution Analysis of 765 Patients from the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2015, 221, 767-777.	0.5	70
28	A Novel Pathology-Based Preoperative Risk Score to Predict Locoregional Residual and Distant Disease and Survival for Incidental Gallbladder Cancer: A 10-Institution Study from the U.S. Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2017, 24, 1343-1350.	1.5	68
29	Impact of body mass index on perioperative outcomes and survival after resection for gastric cancer. Journal of Surgical Research, 2015, 195, 74-82.	1.6	66
30	Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 872-878.	0.3	66
31	Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. Journal of Surgical Oncology, 2015, 111, 1028-1034.	1.7	65
32	Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy. Journal of Gastrointestinal Surgery, 2017, 21, 1841-1850.	1.7	65
33	Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2016, 23, 2398-2408.	1.5	63
34	A Nomogram to Predict Overall Survival and Disease-Free Survival After Curative Resection of Gastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 1828-1835.	1.5	62
35	Impact of complications on longâ€term survival after resection of intrahepatic cholangiocarcinoma. Cancer, 2015, 121, 2730-2739.	4.1	61
36	Conditional Survival after Surgical Resection of Gastric Cancer: A Multi-Institutional Analysis of the US Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 557-564.	1.5	61

#	Article	IF	Citations
37	A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). International Journal of Radiation Oncology Biology Physics, 2016, 96, 296-303.	0.8	61
38	Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme. Journal of the American College of Surgeons, 2016, 222, 750-759e2.	0.5	61
39	Assessing Textbook Outcomes Following Liver Surgery for Primary Liver Cancer Over a 12-Year Time Period at Major Hepatobiliary Centers. Annals of Surgical Oncology, 2020, 27, 3318-3327.	1.5	59
40	Natural History of Patients with Subcentimeter Pulmonary Nodules Undergoing Hepatic Resection for Metastatic Colorectal Cancer. Journal of the American College of Surgeons, 2010, 210, 31-38.	0.5	58
41	Laparoscopic vs Open Right Hepatectomy: A Value-Based Analysis. Journal of the American College of Surgeons, 2014, 218, 929-939.	0.5	58
42	Use of Endoscopic Ultrasound in the Preoperative Staging of Gastric Cancer: A Multi-Institutional Study of the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2015, 220, 48-56.	0.5	58
43	Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: A multiâ€institutional analysis. Journal of Surgical Oncology, 2017, 116, 133-139.	1.7	57
44	Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases. Modern Pathology, 2016, 29, 1575-1585.	5.5	56
45	Intrahepatic cholangiocarcinoma tumor burden: A classification and regression tree model to define prognostic groups after resection. Surgery, 2019, 166, 983-990.	1.9	54
46	Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. JAMA Surgery, 2019, 154, 134.	4.3	54
47	A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2019, 270, 422-433.	4.2	53
48	Conditional Disease-Free Survival After Surgical Resection of Gastrointestinal Stromal Tumors. JAMA Surgery, 2015, 150, 299.	4.3	52
49	Elevated NLR in gallbladder cancer and cholangiocarcinoma â€“ making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 950-957.	0.3	50
50	Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence?. Journal of the American College of Surgeons, 2016, 222, 448-456.	0.5	50
51	The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2018, 25, 1140-1149.	1.5	48
52	Defining Early Recurrence of Hilar Cholangiocarcinoma After Curativeâ€intent Surgery: A Multiâ€institutional Study from the US Extrahepatic Biliary Malignancy Consortium. World Journal of Surgery, 2018, 42, 2919-2929.	1.6	48
53	Natural Orifice Translumenal Endoscopic Surgery in Humans: A Review. Minimally Invasive Surgery, 2012, 2012, 1-8.	0.5	47
54	Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy. Journal of Surgical Oncology, 2016, 114, 440-445.	1.7	47

#	Article	IF	Citations
55	Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. Oncologist, 2016, 21, 178-187.	3.7	47
56	Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Periâ€Operative Outcomes. World Journal of Surgery, 2018, 42, 2551-2560.	1.6	47
57	Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors â‰¥2â€‰cm after curative resection: A multiâ€institutional study of 392 cases. Journal of Surgical Oncology, 2019, 120, 1071-1079.	1.7	47
58	The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis. Hpb, 2016, 18, 700-705.	0.3	46
59	Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis. Annals of Surgical Oncology, 2016, 23, 2998-3008.	1.5	44
60	Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. American Surgeon, 2017, 83, 679-686.	0.8	44
61	The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 2888-2901.	1.5	44
62	Therapeutic Index Associated with Lymphadenectomy Among Patients with Intrahepatic Cholangiocarcinoma: Which Patients Benefit the Most from Nodal Evaluation?. Annals of Surgical Oncology, 2019, 26, 2959-2968.	1.5	43
63	Prognostic Implications of Lymph Node Status for Patients With Gallbladder Cancer: A Multi-Institutional Study. Annals of Surgical Oncology, 2016, 23, 3016-3023.	1.5	42
64	Outcomes after resection of cortisol-secreting adrenocortical carcinoma. American Journal of Surgery, 2016, 211, 1106-1113.	1.8	42
65	Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence. Annals of Surgical Oncology, 2016, 23, 126-133.	1.5	42
66	A Machine-Based Approach to Preoperatively Identify Patients with the Most and Least Benefit Associated withÂResection for Intrahepatic Cholangiocarcinoma: An International Multi-institutional Analysis of 1146 Patients. Annals of Surgical Oncology, 2020, 27, 1110-1119.	1.5	41
67	Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection. Annals of Surgical Oncology, 2011, 18, 2699-2705.	1.5	39
68	Effect of Preoperative Renal Insufficiency on Postoperative Outcomes after Pancreatic Resection: A Single Institution Experience of 1,061 Consecutive Patients. Journal of the American College of Surgeons, 2014, 218, 92-101.	0.5	39
69	Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. Hpb, 2018, 20, 277-284.	0.3	39
70	Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group. Surgery, 2019, 165, 548-556.	1.9	39
71	Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?. Annals of Surgical Oncology, 2016, 23, 708-713.	1.5	38
72	Curative Surgical Resection of Adrenocortical Carcinoma. Annals of Surgery, 2017, 265, 197-204.	4.2	38

#	Article	IF	Citations
73	Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group. Annals of Surgical Oncology, 2019, 26, 2517-2524.	1.5	38
74	Preoperative Risk Score and Prediction of Long-Term Outcomes after Hepatectomy for Intrahepatic Cholangiocarcinoma. Journal of the American College of Surgeons, 2018, 226, 393-403.	0.5	37
75	The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. Hpb, 2020, 22, 1667-1674.	0.3	37
76	Neutrophilâ€lymphocyte and plateletâ€lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2015, 112, 164-172.	1.7	36
77	Frailty and one-year mortality in major intra-abdominal operations. Journal of Surgical Research, 2016, 203, 507-512.e1.	1.6	36
78	Actual 10â€year survivors following resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2016, 114, 971-976.	1.7	36
79	Non-ampullaryâ€“duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas. Modern Pathology, 2017, 30, 255-266.	5.5	36
80	Nomogram predicting the risk of recurrence after curativeâ€intent resection of primary nonâ€metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. Journal of Surgical Oncology, 2018, 117, 868-878.	1.7	36
81	New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2019, Publish Ahead of Print, e28-e35.	4.2	36
82	The Landmark Series: Gallbladder Cancer. Annals of Surgical Oncology, 2020, 27, 2846-2858.	1.5	36
83	The importance of the proximal resection margin distance for proximal gastric adenocarcinoma: A multiâ€institutional study of the US Gastric Cancer Collaborative. Journal of Surgical Oncology, 2015, 112, 203-207.	1.7	35
84	High Nuclear Hypoxia-Inducible Factor 1 AlphaÂExpression Is a Predictor of Distant Recurrence in Patients With Resected PancreaticÂAdenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2015, 91, 631-639.	0.8	35
85	Treatment allocation in patients with earlyâ€stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement. Cancer, 2016, 122, 2150-2157.	4.1	35
86	Neuroendocrine liver metastasis: The chance to be cured after liver surgery. Journal of Surgical Oncology, 2017, 115, 687-695.	1.7	35
87	CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer. Cancer Research, 2014, 74, 2677-2687.	0.9	34
88	The conundrum of < 2-cm pancreatic neuroendocrine tumors: AÂpreoperative risk score to predict lymph node metastases and guide surgical management. Surgery, 2019, 166, 15-21.	1.9	34
89	Actual 5-Year Survivors After Surgical Resection of Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 611-618.	1.5	34
90	Optimal extent of lymphadenectomy for gastric adenocarcinoma: A 7â€institution study of the U.S. gastric cancer collaborative. Journal of Surgical Oncology, 2016, 113, 750-755.	1.7	33

#	Article	IF	Citations
91	A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis. Journal of Gastrointestinal Surgery, 2016, 20, 1098-1105.	1.7	33
92	The relationship of blood transfusion with peri-operative and long-term outcomes after major hepatectomy for metastatic colorectal cancer: a multi-institutional study of 456 patients. Hpb, 2016, 18, 192-199.	0.3	33
93	Is Linitis Plastica a Contraindication for Surgical Resection: A Multi-Institution Study of the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2016, 23, 1203-1211.	1.5	33
94	Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. Hpb, 2016, 18, 510-517.	0.3	33
95	Impact of microvascular invasion on clinical outcomes after curativeâ€intent resection for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2019, 119, 21-29.	1.7	33
96	Preoperative prognostic nutritional index predicts survival of patients with intrahepatic cholangiocarcinoma after curative resection. Journal of Surgical Oncology, 2018, 118, 422-430.	1.7	33
97	Multivisceral Resection for Gastric Cancer: Results from the US Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 840-847.	1.5	32
98	Are the Current Guidelines for the Surgical Management of Intraductal Papillary Mucinous Neoplasms of the Pancreas Adequate? A Multi-Institutional Study. Journal of the American College of Surgeons, 2017, 224, 461-469.	0.5	32
99	Oncologic effects of preoperative biliary drainage in resectable hilar cholangiocarcinoma: Percutaneous biliary drainage has no adverse effects on survival. Journal of Surgical Oncology, 2018, 117, 1267-1277.	1.7	32
100	Value of Primary Operative Drain Placement after Major Hepatectomy: A Multi-Institutional Analysis of 1,041 Patients. Journal of the American College of Surgeons, 2015, 220, 396-402.	0.5	31
101	Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases. Annals of Surgical Oncology, 2015, 22, 4392-4401.	1.5	31
102	A Comparison of Prognostic Schemes for Perihilar Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 1716-1724.	1.7	31
103	Decreasing Hospital Readmission in Ileostomy Patients: Results of Novel Pilot Program. Journal of the American College of Surgeons, 2017, 224, 425-430.	0.5	31
104	Impact of Morphological Status on Long-Term Outcome Among Patients Undergoing Liver Surgery for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2017, 24, 2491-2501.	1.5	31
105	Defining Long-Term Survivors Following Resection of Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2017, 21, 1888-1897.	1.7	31
106	Development and Validation of a Laboratory Risk Score (LabScore) to Predict Outcomes after Resection for Intrahepatic Cholangiocarcinoma. Journal of the American College of Surgeons, 2020, 230, 381-391e2.	0.5	31
107	Improving the clinical risk score: An analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. Surgery, 2012, 151, 162-170.	1.9	30
108	Assessing the impact of common bile duct resection in the surgical management of gallbladder cancer. Journal of Surgical Oncology, 2016, 114, 176-180.	1.7	30

#	Article	IF	Citations
109	Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable?. Journal of Gastrointestinal Surgery, 2017, 21, 1245-1253.	1.7	30
110	Association of preoperative monocyteâ€toâ€lymphocyte and neutrophilâ€toâ€lymphocyte ratio with recurrenceâ€free and overall survival after resection of pancreatic neuroendocrine tumors (USâ€NETSG). Journal of Surgical Oncology, 2019, 120, 632-638.	1.7	30
111	Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Molecular Cancer Therapeutics, 2021, 20, 150-160.	4.1	30
112	Tumor Burden Dictates Prognosis Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma: A Tool to Guide Post-Resection Adjuvant Chemotherapy?. Annals of Surgical Oncology, 2021, 28, 1970-1978.	1.5	30
113	Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. Cancer Research and Treatment, 2016, 48, 596-604.	3.0	30
114	The importance of surgical margins in gastric cancer. Journal of Surgical Oncology, 2016, 113, 277-282.	1.7	29
115	Small bowel neuroendocrine tumors: A critical analysis of diagnostic workâ€up and operative approach. Journal of Surgical Oncology, 2016, 114, 671-676.	1.7	29
116	The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: a multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium. Surgery, 2018, 163, 726-731.	1.9	29
117	Minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: An analysis from the U.S. neuroendocrine tumor study group. Journal of Surgical Oncology, 2019, 120, 231-240.	1.7	29
118	Surgical Management of Advanced Gastrointestinal Stromal Tumors: An International Multi-Institutional Analysis of 158 Patients. Journal of the American College of Surgeons, 2014, 219, 439-449.	0.5	28
119	The Prognostic Value of Signet-Ring Cell Histology in Resected Gastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 832-839.	1.5	28
120	To Roux or not to Roux: a comparison between Roux-en-Y and Billroth II reconstruction following partial gastrectomy for gastric cancer. Gastric Cancer, 2016, 19, 994-1001.	5.3	28
121	Routine portâ€site excision in incidentally discovered gallbladder cancer is not associated with improved survival: A multiâ€institution analysis from the US Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology, 2017, 115, 805-811.	1.7	28
122	Distal Cholangiocarcinoma and Pancreas Adenocarcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium. Journal of the American College of Surgeons, 2017, 224, 406-413.	0.5	28
123	Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. Hpb, 2018, 20, 956-965.	0.3	28
124	Preoperative quantification of perceptions of surgical frailty. Journal of Surgical Research, 2015, 193, 583-589.	1.6	27
125	Survival after resection of perihilar cholangiocarcinoma inÂpatients with lymph node metastases. Hpb, 2017, 19, 735-740.	0.3	27
126	Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma. Surgery, 2018, 163, 1114-1120.	1.9	27

#	Article	IF	Citations
127	Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. Hpb, 2018, 20, 332-339.	0.3	27
128	Should Utilization of Lymphadenectomy Vary According to Morphologic Subtype of Intrahepatic Cholangiocarcinoma?. Annals of Surgical Oncology, 2019, 26, 2242-2250.	1.5	27
129	Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative. Journal of Gastrointestinal Surgery, 2020, 24, 155-164.	1.7	27
130	An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma: A sevenâ€institution analysis of 837 patients from the U.S. gastric cancer collaborative. Journal of Surgical Oncology, 2015, 112, 195-202.	1.7	26
131	Outcomes of Gastric Cancer Resection in Octogenarians: A Multi-institutional Study of the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 4371-4379.	1.5	26
132	Stage-Specific Prognostic Effect of Race in Patients with Resectable Gastric Adenocarcinoma: An 8-Institution Study of the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2016, 222, 633-643.	0.5	26
133	Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study. Journal of Gastrointestinal Surgery, 2020, 24, 165-176.	1.7	26
134	Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers. Oncologist, 2015, 20, 907-914.	3.7	25
135	Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy. Surgery, 2017, 162, 285-294.	1.9	25
136	Evaluating the American College of Surgeons National Surgical Quality Improvement project risk calculator: results from the U.S. Extrahepatic Biliary Malignancy Consortium. Hpb, 2017, 19, 1104-1111.	0.3	25
137	Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience. Annals of Surgical Oncology, 2017, 24, 2770-2776.	1.5	25
138	Updates on Gallbladder Cancer Management. Current Oncology Reports, 2018, 20, 21.	4.0	25
139	Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2022, 157, 590.	4.3	25
140	Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma. Journal of the American College of Surgeons, 2016, 223, 794-803.	0.5	24
141	Does Surgical Margin Impact Recurrence in Noninvasive Intraductal Papillary Mucinous Neoplasms?. Annals of Surgery, 2018, 268, 469-478.	4.2	24
142	Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: An analysis of the US extrahepatic biliary malignancy consortium. Journal of Surgical Oncology, 2020, 121, 503-510.	1.7	24
143	Preoperative Helicobacter pylori Infection is Associated with Increased Survival After Resection of Gastric Adenocarcinoma. Annals of Surgical Oncology, 2016, 23, 1225-1233.	1.5	23
144	Incidence and impact of Textbook Outcome among patients undergoing resection of pancreatic neuroendocrine tumors: Results of the US Neuroendocrine Tumor Study Group. Journal of Surgical Oncology, 2020, 121, 1201-1208.	1.7	23

#	Article	IF	Citations
145	Risk Stratification for Readmission after Major Hepatectomy: Development of a Readmission Risk Score. Journal of the American College of Surgeons, 2015, 220, 640-648.	0.5	22
146	Changing Odds of Survival Over Time among Patients Undergoing Surgical Resection of Gallbladder Carcinoma. Annals of Surgical Oncology, 2016, 23, 4401-4409.	1.5	22
147	Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms. Journal of Gastrointestinal Surgery, 2019, 23, 122-134.	1.7	22
148	The Effect of Preoperative Renal Insufficiency on Postoperative Outcomes after Major Hepatectomy: A Multi-Institutional Analysis of 1,170 Patients. Journal of the American College of Surgeons, 2014, 219, 914-922.	0.5	21
149	Race, ethnicity, and socioeconomic factors in cholangiocarcinoma: What is driving disparities in receipt of treatment?. Journal of Surgical Oncology, 2019, 120, 611-623.	1.7	21
150	Caution: Increased Acute Kidney Injury in Enhanced Recovery after Surgery (ERAS) Protocols. American Surgeon, 2019, 85, 156-161.	0.8	21
151	Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis. Annals of Surgical Oncology, 2020, 27, 1203-1212.	1.5	21
152	Optimal timing and treatment strategy for pancreatic cancer. Journal of Surgical Oncology, 2020, 122, 457-468.	1.7	21
153	Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. Journal of Surgical Oncology, 2020, 121, 1067-1073.	1.7	21
154	Defining and Predicting Early Recurrence after Resection for Gallbladder Cancer. Annals of Surgical Oncology, 2021, 28, 417-425.	1.5	21
155	Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined. Journal of Surgical Oncology, 2019, 120, 1302-1310.	1.7	20
156	In Patients with Localized and Resectable Gastric Cancer, What is the Optimal Extent of Lymph Node Dissectionâ€"D1 Versus D2 Versus D3?. Annals of Surgical Oncology, 2019, 26, 2912-2932.	1.5	20
157	Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence. Hpb, 2020, 22, 215-223.	0.3	20
158	A Novel Classification of Intrahepatic Cholangiocarcinoma Phenotypes Using Machine Learning Techniques: An International Multi-Institutional Analysis. Annals of Surgical Oncology, 2020, 27, 5224-5232.	1.5	20
159	Predicting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2021, 25, 1156-1163.	1.7	20
160	Impact of Postoperative Complications on Oncologic Outcomes After Rectal Cancer Surgery: An Analysis of the US Rectal Cancer Consortium. Annals of Surgical Oncology, 2021, 28, 1712-1721.	1.5	20
161	A 15-year experience with gastric neuroendocrine tumors: Does type make a difference?. Journal of Surgical Oncology, 2016, 114, 576-580.	1.7	19
162	Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer. World Journal of Surgery, 2017, 41, 224-231.	1.6	19

#	Article	IF	Citations
163	Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database. Annals of Surgical Oncology, 2018, 25, 2308-2315.	1.5	19
164	Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. Annals of Surgical Oncology, 2019, 26, 3542-3549.	1.5	19
165	Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel?. Journal of Surgical Oncology, 2019, 120, 1293-1301.	1.7	19
166	Optimizing cancer care for hepatocellular carcinoma at a safetyâ€net hospital: The value of a multidisciplinary disease management team. Journal of Surgical Oncology, 2019, 120, 1365-1370.	1.7	19
167	Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2019, 26, 1814-1823.	1.5	19
168	Defining the Risk of Early Recurrence Following Curative-Intent Resection for Distal Cholangiocarcinoma. Annals of Surgical Oncology, 2021, 28, 4205-4213.	1.5	19
169	The value of a crossâ€discipline teamâ€based approach for resection of renal cell carcinoma with IVC tumor thrombus: A report of a large, contemporary, singleâ€institution experience. Journal of Surgical Oncology, 2018, 118, 1219-1226.	1.7	18
170	Long-term outcomes of patients with intraductal growth sub-type of intrahepatic cholangiocarcinoma. Hpb, 2018, 20, 1189-1197.	0.3	18
171	Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: A multiâ€institutional analysis. Journal of Surgical Oncology, 2019, 120, 1080-1086.	1.7	18
172	Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors. Hpb, 2021, 23, 413-421.	0.3	18
173	Gastric remnant cancer: A distinct entity or simply another proximal gastric cancer?. Journal of Surgical Oncology, 2015, 112, 877-882.	1.7	17
174	Proposal for a new T-stage classification system for distal cholangiocarcinoma: a 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 793-799.	0.3	17
175	Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curativeâ€intent Resection: a Multiâ€institutional Study. World Journal of Surgery, 2018, 42, 849-857.	1.6	17
176	Value of Peritoneal Drain Placement After Total Gastrectomy for Gastric Adenocarcinoma: A Multi-institutional Analysis from the US Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 888-897.	1.5	16
177	Assessing Trends in Palliative Surgery for Extrahepatic Biliary Malignancies: A 15-Year Multicenter Study. Journal of Gastrointestinal Surgery, 2016, 20, 1444-1452.	1.7	16
178	The Limitations of Standard Clinicopathologic Features to Accurately Risk-Stratify Prognosis after Resection of Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2018, 22, 477-485.	1.7	16
179	Timing of disease occurrence and hepatic resection on longâ€term outcome of patients with neuroendocrine liver metastasis. Journal of Surgical Oncology, 2018, 117, 171-181.	1.7	16
180	Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. Surgery, 2019, 165, 657-663.	1.9	16

#	Article	IF	Citations
181	Conditional survival analysis of hepatocellular carcinoma. Journal of Surgical Oncology, 2020, 122, 684-690.	1.7	16
182	Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Longâ€Term Survival. World Journal of Surgery, 2016, 40, 706-714.	1.6	15
183	The diagnosis of pancreatic mucinous cystic neoplasm and associated adenocarcinoma in males: An eightâ€institution study of 349 patients over 15 years. Journal of Surgical Oncology, 2017, 115, 784-787.	1.7	15
184	The impact of extrahepatic disease among patients undergoing liverâ€directed therapy for neuroendocrine liver metastasis. Journal of Surgical Oncology, 2017, 116, 841-847.	1.7	15
185	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. Annals of Surgical Oncology, 2018, 25, 520-527.	1.5	15
186	Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. Oncologist, 2018, 23, 704-711.	3.7	15
187	Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease. Annals of Surgical Oncology, 2018, 25, 290-298.	1.5	15
188	Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Surgery, 2019, 23, 651-658.	1.7	15
189	Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Cancer, 2019, 125, 57-67.	4.1	15
190	Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 4980-4995.	1.5	15
191	Clinical relevance of performing endoscopic ultrasoundâ€guided fineâ€needle biopsy for pancreatic neuroendocrine tumors less than 2â€‰cm. Journal of Surgical Oncology, 2020, 122, 1393-1400.	1.7	15
192	Lung Surveillance Strategy for High-Grade Soft Tissue Sarcomas: Chest X-Ray or CT Scan?. Journal of the American College of Surgeons, 2019, 229, 449-457.	0.5	14
193	Approaches and Outcomes to Distal Cholangiocarcinoma. Surgical Oncology Clinics of North America, 2019, 28, 631-643.	1.5	14
194	Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 134-146.	1.5	14
195	What is the Optimal Preoperative Imaging Modality for Assessing Peritoneal Cancer Index? An Analysis From the United States HIPEC Collaborative. Clinical Colorectal Cancer, 2020, 19, e1-e7.	2.3	14
196	A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer. Annals of Surgery, 2021, 274, e82-e84.	4.2	14
197	Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy. Chinese Clinical Oncology, 2020, 9, 4-4.	1.2	14
198	Studying a Rare Disease Using Multi-Institutional Research Collaborations vs Big Data: Where Lies the Truth?. Journal of the American College of Surgeons, 2018, 227, 357-366e3.	0.5	13

#	Article	IF	Citations
199	Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 156-164.	1.5	13
200	In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. Journal of Geriatric Oncology, 2020, 11, 660-667.	1.0	13
201	Tumor burden score predicts tumor recurrence of non-functional pancreatic neuroendocrine tumors after curative resection. Hpb, 2020, 22, 1149-1157.	0.3	13
202	Pancreatic ductal adenocarcinomas associated with intraductal papillary mucinous neoplasms (IPMNs) versus pseudo-IPMNs: relative frequency, clinicopathologic characteristics and differential diagnosis. Modern Pathology, 2022, 35, 96-105.	5.5	13
203	Development and Validation of a Modified Eighth AJCC Staging System for Primary Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2022, 275, e773-e780.	4.2	13
204	Evaluation and management of incidental gallbladder cancer. Chinese Clinical Oncology, 2019, 8, 37-37.	1.2	13
205	Prognostic impact of perineural invasion in intrahepatic cholangiocarcinoma: multicentre study. British Journal of Surgery, 2022, 109, 610-616.	0.3	13
206	Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies. Journal of Gastrointestinal Surgery, 2017, 21, 1813-1820.	1.7	12
207	Blood Transfusion and Survival for Resected Adrenocortical Carcinoma: A Study from the United States Adrenocortical Carcinoma Group. American Surgeon, 2017, 83, 761-768.	0.8	12
208	The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study. Journal of Gastrointestinal Surgery, 2019, 23, 484-491.	1.7	12
209	Staging laparoscopy among three subtypes of extraâ€hepatic biliary malignancy: a 15â€year experience from 10 institutions. Journal of Surgical Oncology, 2019, 119, 288-294.	1.7	12
210	Bile cultures are poor predictors of antibiotic resistance in postoperative infections following pancreaticoduodenectomy. Hpb, 2020, 22, 969-978.	0.3	12
211	Long-Term Outcomes after Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors: Results from the US Neuroendocrine Study Group. Neuroendocrinology, 2021, 111, 129-138.	2.5	12
212	Predictors and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer. Journal of Gastrointestinal Surgery, 2017, 21, 1984-1992.	1.7	11
213	The Oncologic Impact of Postoperative Complications Following Resection of Truncal and Extremity Soft Tissue Sarcomas. Annals of Surgical Oncology, 2017, 24, 3574-3586.	1.5	11
214	Accuracy of the ACS NSQIP Online Risk Calculator Depends on How You Look at It: Results from the United States Gastric Cancer Collaborative. American Surgeon, 2018, 84, 358-364.	0.8	11
215	A novel preoperative risk score to predict lymph node positivity for rectal neuroendocrine tumors: An NCDB analysis to guide operative technique. Journal of Surgical Oncology, 2019, 120, 932-939.	1.7	11
216	Gastric carcinoids: Does type of surgery or tumor affect survival?. American Journal of Surgery, 2019, 217, 937-942.	1.8	11

#	Article	IF	Citations
217	Features of synchronous versus metachronous metastasectomy in adrenal cortical carcinoma: Analysis from the US adrenocortical carcinoma database. Surgery, 2020, 167, 352-357.	1.9	11
218	Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy. Cancer, 2020, 126, 37-45.	4.1	11
219	The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC. Annals of Surgical Oncology, 2020, 27, 4894-4907.	1.5	11
220	Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study. Annals of Surgical Oncology, 2020, 27, 4883-4891.	1.5	11
221	Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database. Annals of Surgical Oncology, 2021, 28, 6551-6561.	1.5	11
222	Human hybrid endoscopic and laparoscopic management of mass lesions of the foregut (with video). Gastrointestinal Endoscopy, 2012, 75, 905-912.	1.0	10
223	Determination of Resectability. Surgical Clinics of North America, 2016, 96, 163-181.	1.5	10
224	Clinicopathologic score predicting lymph node metastasis in T1 gastric cancer. Surgery, 2018, 163, 889-893.	1.9	10
225	Association of perioperative transfusion with survival and recurrence after resection of gallbladder cancer: A 10â€institution study from the US Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology, 2018, 117, 1638-1647.	1.7	10
226	Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity?. Journal of Surgical Oncology, 2019, 120, 919-925.	1.7	10
227	Conditional diseaseâ€free survival after curativeâ€intent liver resection for neuroendocrine liver metastasis. Journal of Surgical Oncology, 2019, 120, 1087-1095.	1.7	10
228	Evaluating the ACS NSQIP Risk Calculator in Primary Pancreatic Neuroendocrine Tumor: Results from the US Neuroendocrine Tumor Study Group. Journal of Gastrointestinal Surgery, 2019, 23, 2225-2231.	1.7	10
229	Influence of margin histology on development ofÂpancreatic fistula following pancreatoduodenectomy. Journal of Surgical Research, 2020, 246, 315-324.	1.6	10
230	Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers. Hpb, 2020, 22, 1675-1685.	0.3	10
231	T2 gallbladder cancer shows substantial survival variation between continents and this is not due to histopathologic criteria or pathologic sampling differences. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 875-884.	2.8	10
232	Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis. Annals of Surgical Oncology, 2021, 28, 4499-4507.	1.5	10
233	Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study. Hpb, 2021, 23, 422-433.	0.3	10
234	Proposed modification of the eighth edition of the AJCC staging system for intrahepatic cholangiocarcinoma. Hpb, 2021, 23, 1456-1466.	0.3	10

#	Article	IF	Citations
235	Colon and Rectal Neuroendocrine Tumors: Are They Really One Disease? A Single-Institution Experience over 15 Years. American Surgeon, 2018, 84, 717-726.	0.8	9
236	The Prognostic Value of Lymphovascular Invasion in Truncal and Extremity Soft Tissue Sarcomas: An Analysis from the National Cancer Database. Annals of Surgical Oncology, 2019, 26, 4723-4729.	1.5	9
237	Perioperative anxiety and depression in patients undergoing abdominal surgery for benign or malignant disease. Journal of Surgical Oncology, 2019, 120, 389-396.	1.7	9
238	Identifying the barriers to gastric cancer care at safetyâ€net hospitals: A novel comparison of a safetyâ€net hospital to a neighboring quaternary referral academic center in the same healthcare system. Journal of Surgical Oncology, 2019, 119, 64-70.	1.7	9
239	Cyst location and presence of high grade dysplasia or invasive cancer in intraductal papillary mucinous neoplasms of the pancreas: a seven institution study from the central pancreas consortium. Hpb, 2019, 21, 482-488.	0.3	9
240	Surgical treatment of gastric adenocarcinoma: Are we achieving textbook oncologic outcomes for our patients?. Journal of Surgical Oncology, 2022, 125, 621-630.	1.7	9
241	Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. Journal of Surgical Oncology, 2016, 114, 336-341.	1.7	8
242	Perception Is Reality: quality metrics in pancreas surgery â€“ a Central Pancreas Consortium (CPC) analysis of 1399 patients. Hpb, 2016, 18, 462-469.	0.3	8
243	Dissecting disease, race, ethnicity, and socioeconomic factors for hepatocellular carcinoma: An analysis from the United States Safety Net Collaborative. Surgical Oncology, 2020, 35, 120-125.	1.6	8
244	Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review. Hepatobiliary Surgery and Nutrition, 2022, 11, 253-266.	1.5	8
245	Outcomes in Patients with Renal Cell Carcinoma Undergoing Inferior Vena Cava Ligation without Reconstruction versus Thrombectomy: A Retrospective, Case Controlled Study. Journal of Urology, 2021, 205, 383-391.	0.4	8
246	Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2022, 29, 1220-1229.	1.5	8
247	Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. American Surgeon, 2019, 85, 1334-1340.	0.8	7
248	Development of a Surgical Evidence Blog at Morbidity and Mortality Conferences: Integrating Clinical Librarians to Enhance Resident Education. Journal of Surgical Education, 2020, 77, 1069-1075.	2.5	7
249	A US Rectal Cancer Consortium Study of Inferior Mesenteric Artery Versus Superior Rectal Artery Ligation: How High Do We Need to Go?. Diseases of the Colon and Rectum, 2021, 64, 1198-1211.	1.3	7
250	A novel preoperative risk score to guide patient selection for resection of soft tissue sarcoma lung metastases: An analysis from the United States Sarcoma Collaborative. Journal of Surgical Oncology, 2021, 124, 1477-1484.	1.7	7
251	The aborted Whipple: Why, and what happens next?. Journal of Surgical Oncology, 2022, 125, 642-645.	1.7	7
252	Tumor Necrosis Impacts Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2022, 29, 4326-4334.	1.5	7

#	Article	IF	Citations
253	Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years. Journal of Surgical Oncology, 2016, 114, 163-169.	1.7	6
254	The prognostic significance of adrenocortical carcinomas identified incidentally. Journal of Surgical Oncology, 2018, 118, 1155-1162.	1.7	6
255	Should Signet Ring Cell Histology Alter the Treatment Approach for Clinical Stage I Gastric Cancer?. Annals of Surgical Oncology, 2021, 28, 97-105.	1.5	6
256	Does Major Pancreatic Surgery Have Utility in Nonagenarians with Pancreas Cancer?. Annals of Surgical Oncology, 2021, 28, 2265-2272.	1.5	6
257	Relationship between Cancer Diagnosis and Complications Following Pancreatoduodenectomy for Duodenal Adenoma. Annals of Surgical Oncology, 2021, 28, 1097-1105.	1.5	6
258	Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. Cancers, 2021, 13, 2242.	3.7	6
259	Are We Undertreating Black Patients with Nonfunctional Pancreatic Neuroendocrine Tumors? Critical Analysis of Current Surveillance Guidelines by Race. Journal of the American College of Surgeons, 2022, 234, 599-606.	0.5	6
260	A multiâ€institutional analysis of 429 patients undergoing major hepatectomy for colorectal cancer liver metastases: The impact of concomitant bile duct resection on survival. Journal of Surgical Oncology, 2015, 112, 524-528.	1.7	5
261	The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An 8â€institution study from the US Neuroendocrine Tumor Study Group. Journal of Surgical Oncology, 2019, 119, 5-11.	1.7	5
262	STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?. Journal of Gastrointestinal Surgery, 2020, 24, 1138-1148.	1.7	5
263	Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group. Hpb, 2020, 22, 1042-1050.	0.3	5
264	Redefining Conditional Overall and Disease-Free Survival After Curative Resection for Intrahepatic Cholangiocarcinoma: a Multi-institutional, International Study of 1221 patients. Journal of Gastrointestinal Surgery, 2020, 24, 2756-2765.	1.7	5
265	Appendiceal Neuroendocrine Tumors: Does Colon Resection Improve Outcomes?. Journal of Gastrointestinal Surgery, 2020, 24, 2121-2126.	1.7	5
266	Predictors of Non-home Discharge after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Journal of Surgical Research, 2020, 255, 475-485.	1.6	5
267	Should adenosquamous esophageal cancer be treated like adenocarcinoma or squamous cell carcinoma?. Journal of Surgical Oncology, 2020, 122, 412-421.	1.7	5
268	Emergency department visits after pancreatoduodenectomy: examining a novel quality metric. Hpb, 2020, 22, 757-763.	0.3	5
269	Perioperative Versus Adjuvant Chemotherapy in the Management of Incidentally Found Gallbladder Cancer (OPT-IN). Annals of Surgical Oncology, 2022, 29, 37-38.	1.5	5
270	Surgical Strategies for Bismuth Type I and II Hilar Cholangiocarcinoma: Impact on Long-Term Outcomes. Journal of Gastrointestinal Surgery, 2021, 25, 3084-3091.	1.7	5

#	Article	IF	Citations
271	ASO Visual Abstract: Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 734-735.	1.5	5
272	Molecular targeted therapy for biliary tract malignancy: defining the target. Hepatobiliary Surgery and Nutrition, 2012, 1, 53-4.	1.5	5
273	Hybrid Push-Pull Endoscopic and Laparoscopic Full Thickness Resection for the Minimally Invasive Management of Gastrointestinal Stromal Tumors: A Pilot Clinical Study. Gastroenterology Research and Practice, 2015, 2015, 1-7.	1.5	4
274	A novel, simplified, externally validated staging system for truncal/extremity soft tissue sarcomas: An analysis of the US Sarcoma Collaborative database. Journal of Surgical Oncology, 2018, 118, 1135-1141.	1.7	4
275	Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. British Journal of Cancer, 2020, 123, 1377-1386.	6.4	4
276	The Evolving Landscape of Hepatocellular Carcinoma. American Surgeon, 2020, 86, 865-872.	0.8	4
277	Revisiting the Value of Drains After Low Anterior Resection for Rectal Cancer: a Multi-institutional Analysis of 996 Patients. Journal of Gastrointestinal Surgery, 2021, 25, 2000-2010.	1.7	4
278	Impact of Insurance Status on Survival in Gastroenteropancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2020, 27, 3147-3153.	1.5	4
279	A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC. Journal of Surgical Oncology, 2021, 123, 187-195.	1.7	4
280	The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. Journal of Gastrointestinal Surgery, 2021, 25, 2908-2919.	1.7	4
281	Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report. Frontiers in Oncology, 2020, 10, 622134.	2.8	4
282	The Undertreatment of Gallbladder Cancer: Gaps in Seeking, Reaching, and Receiving Care. Annals of Surgical Oncology, 2021, 28, 2925-2927.	1.5	4
283	Surgical Treatment of Neuroendocrine Tumors of the Terminal Ileum or Cecum: Ileocecectomy Versus Right Hemicolectomy. Journal of Gastrointestinal Surgery, 2022, 26, 1266-1274.	1.7	4
284	Neoadjuvant therapy trials in biliary tract malignancies. Journal of Surgical Oncology, 2022, 125, 84-88.	1.7	4
285	Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium. Annals of Surgical Oncology, 2022, 29, 6004-6012.	1.5	4
286	Surgical outcomes of gastroâ€enteroâ€pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma. Journal of Surgical Oncology, 2022, 126, 689-697.	1.7	4
287	The Hand-Assisted Laparoscopic Approach to Resection of Pancreatic Mucinous Cystic Neoplasms: An Underused Technique?. American Surgeon, 2018, 84, 56-62.	0.8	3
288	Fertility after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A call to action. Journal of Surgical Oncology, 2021, 123, 1045-1049.	1.7	3

#	Article	IF	Citations
289	Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative. Journal of Gastrointestinal Surgery, 2022, 26, 414-424.	1.7	3
290	Neoadjuvant treatment of pancreatic carcinosarcoma: a case report and review of literature. Chinese Clinical Oncology, 2022, 11, 8-8.	1.2	3
291	Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. American Surgeon, 2019, 85, 1334-1340.	0.8	3
292	Surgical resection for adrenocortical carcinoma: Current trends affecting survival. Journal of Surgical Oncology, 2022, 125, 1224-1230.	1.7	3
293	Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer. Clinical Cancer Research, 2022, 28, 4336-4345.	7.0	3
294	Patient reported outcomes: Financial toxicity is a barrier to clinical trials and personalized therapy in cholangiocarcinoma. Journal of Surgical Oncology, 2022, 126, 1003-1010.	1.7	3
295	Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma. Journal of Gastrointestinal Surgery, 2015, 19, 2154-2161.	1.7	2
296	Post-hepatectomy hyperbilirubinemia: The point of no return. American Journal of Surgery, 2017, 214, 93-99.	1.8	2
297	A Multi-Institutional Study Comparing the Use of the American Joint Committee on Cancer 7th Edition Esophageal versus Gastric Staging System for Gastroesophageal Junction Cancer in a Western Population. American Surgeon, 2017, 83, 82-89.	0.8	2
298	Paraneoplastic Thrombocytopenia Cured With Nephrectomy and Vena Cava Thrombectomy: Concurrent Hematology and Oncology Management Conundrums. Journal of Oncology Practice, 2017, 13, 767-768.	2.5	2
299	Lending a hand for laparoscopic distal pancreatectomy: the optimal approach?. Hpb, 2020, 22, 690-701.	0.3	2
300	A closer look at the natural history and recurrence patterns of high-grade truncal/extremity leiomyosarcomas: A multi-institutional analysis from the US Sarcoma Collaborative. Surgical Oncology, 2020, 34, 292-297.	1.6	2
301	Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group. Annals of Surgical Oncology, 2020, 27, 3915-3923.	1.5	2
302	Differences in outcome for patients with cholangiocarcinoma: Racial/ethnic disparity or socioeconomic factors?. Surgical Oncology, 2020, 34, 126-133.	1.6	2
303	Recurrence of Nonâ€functional Pancreatic Neuroendocrine Tumors After Curative Resection: A Tumor Burdenâ€Based Prediction Model. World Journal of Surgery, 2021, 45, 2134-2141.	1.6	2
304	Is there a difference in utilization of a perioperative treatment approach for gastric cancer between safety net hospitals and tertiary referral centers?. Journal of Surgical Oncology, 2021, 124, 551-559.	1.7	2
305	Radiotherapy patterns of care in gastric adenocarcinoma: a single institution experience. Journal of Gastrointestinal Oncology, 2015, 6, 247-53.	1.4	2
306	Role of Resection of the Primary in Metastatic Well-Differentiated Neuroendocrine Tumors. Pancreas, 2021, 50, 1382-1391.	1.1	2

#	Article	IF	Citations
307	Defining the role of systemic therapy in resectable pancreatic acinar cell carcinoma. Journal of Surgical Oncology, 2022, 125, 856-864.	1.7	2
308	Negative surgical margins: Main course or just icing on the cake?. Journal of Surgical Oncology, 2016, 113, 247-247.	1.7	1
309	Cholangiocarcinoma size on magnetic resonance imaging versus pathologic specimen: Implications for radiation treatment planning. Practical Radiation Oncology, 2016, 6, 201-206.	2.1	1
310	ASO Author Reflections: Association of Perioperative Red Blood Cell Transfusion with Increased Disease Recurrence and Worse Survival After Resection of Distal Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 654-655.	1.5	1
311	HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target. Surgical Oncology, 2020, 35, 460-465.	1.6	1
312	Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy. Journal of Surgical Oncology, 2020, 122, 442-449.	1.7	1
313	Association of ABO blood group with survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Hpb, 2020, 22, 1557-1562.	0.3	1
314	ASO Author Reflections: A Surgery-First Approach for Patients With Clinical Stage 1 Signet Ring Cell Gastric Adenocarcinoma. Annals of Surgical Oncology, 2020, 27, 781-782.	1.5	1
315	Optimal surgical management of T2 gallbladder cancerâ€“wedge resection. Surgery, 2021, 169, 1312-1313.	1.9	1
316	Radiological assessment of persistent retroperitoneal and lateral pelvic lymph nodes after neoadjuvant therapy for rectal cancer: An analysis of the United States Rectal Cancer Consortium. Journal of Surgical Oncology, 2021, 124, 818-828.	1.7	1
317	Adjuvant treatment for resected sub-centimeter T1 pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, 4125-4125.	1.6	1
318	Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, 38-38.	1.6	1
319	Metastatic colorectal cancer: potential for cure?. Oncology, 2012, 26, 284-5.	0.5	1
320	Implications of leukocytosis following distal pancreatectomy splenectomy (DPS) and association with postoperative complications. Journal of Surgical Oncology, 0, , .	1.7	1
321	Current Status of Imaging to Evaluate Liver Metastases From Colorectal Cancer. Current Colorectal Cancer Reports, 2015, 11, 168-177.	0.5	0
322	Response: increased complications associated with feeding jejunostomy in gastrectomy for gastric cancer: Chicken or the egg?. Journal of Surgical Oncology, 2016, 113, 121-121.	1.7	0
323	ASO Author Reflections: Incorporating Lymphovascular Invasion to Improve the Prognostic Reliability of the T-Staging System for Adrenocortical Carcinomaâ€”A Multicenter Study. Annals of Surgical Oncology, 2018, 25, 862-863.	1.5	0
324	Utility of Intraoperative Margin Assessment by Frozen Section in Gastric Cancer. Annals of Surgical Oncology, 2019, 26, 3782-3783.	1.5	0

#	Article	IF	Citations
325	ASO Author Reflections: Lymph Node Metastasis and the Role for Lymphadenectomy During Surgery for Nonfunctional Pancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2019, 26, 700-701.	1.5	0
326	The Path to Whipple Reconstruction for Pancreatic Adenocarcinoma: Trans-Mesocolon or Through Ligament of Treitz?. Journal of Gastrointestinal Surgery, 2020, 24, 2046-2053.	1.7	0
327	Response to a Letter to the Editor: â€œThe conundrum of <2 cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.â€• Surgery, 2020, 167, 514-515.	1.9	0
328	Relevant Clinical Trials for GI Surgeons: a Review of Recent Findings. Journal of Gastrointestinal Surgery, 2020, 24, 2318-2335.	1.7	0
329	Hepatocellular carcinoma: current state and future horizons. Chinese Clinical Oncology, 2021, 10, 1-1.	1.2	0
330	ASO Author Reflections: Chemoradiation as the Mainstay of Therapy for Nonagenarians with Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 2273-2274.	1.5	0
331	ASO Visual Abstract: Does Major Pancreatic Surgery have Utility for Nonagenarians with Pancreas Cancer?. Annals of Surgical Oncology, 2021, 28, 2275-2276.	1.5	0
332	Neuroendocrine tumors (NET) of the gastrointestinal tract: Patterns of management and experience at Winship Cancer Institute of Emory University.. Journal of Clinical Oncology, 2013, 31, 326-326.	1.6	0
333	A novel simplified approach to incorporating lymph node ratio into gastric cancer staging.. Journal of Clinical Oncology, 2013, 31, 24-24.	1.6	0
334	Differential HER2 expression in resected gastric cancer: Is there prognostic value?. Journal of Clinical Oncology, 2013, 31, 54-54.	1.6	0
335	Survival outcome of ampullary and duodenal adenocarcinomas.. Journal of Clinical Oncology, 2013, 31, e14579-e14579.	1.6	0
336	The effect of perioperative transfusion on recurrence and survival following gastric cancer resection: A seven-institution analysis of 765 patients from the U.S. Gastric Cancer Collaborative.. Journal of Clinical Oncology, 2014, 32, 100-100.	1.6	0
337	Utility of the proximal margin frozen section for resection of gastric adenocarcinoma: A 7-institution study of the U.S. gastric cancer collaborative.. Journal of Clinical Oncology, 2014, 32, 103-103.	1.6	0
338	Difference in outcomes among patients undergoing open versus laparoscopy-assisted approach for gastric cancer: A multi-institutional analysis.. Journal of Clinical Oncology, 2014, 32, 4082-4082.	1.6	0
339	Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: A multi-institutional analysis.. Journal of Clinical Oncology, 2014, 32, 4011-4011.	1.6	0
340	Survival outcomes in gastric and gastroesophageal junction adenocarcinoma treated with peri-operative chemotherapy with or without pre-operative radiotherapy.. Journal of Clinical Oncology, 2018, 36, 4026-4026.	1.6	0
341	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group. VideoEndocrinology, 2018, 5, .	0.1	0
342	ASO Visual Abstract: Tumor Necrosis Impacts the Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2022, , 1.	1.5	0

#	Article	IF	Citations
343	Dynamic Prediction of Survival after Curative Resection of Gastric Adenocarcinoma: A landmarking-based analysis. European Journal of Surgical Oncology, 2021, , .	1.0	0
344	Introduction: Surgeons establishing the landscape of contemporary clinical trials in oncology. Journal of Surgical Oncology, 2022, 125, 5-6.	1.7	0